Highlights

• Orthocell shares rose 4.17% during the morning session on 3 July 2026 following a commercial update.

• MediTime has been appointed as the exclusive distributor for Remplir in Thailand.

• The agreement provides access to Thailand's estimated US$84 million nerve repair market.

• The appointment extends Orthocell's existing relationship with Device Technologies Group across the region.

• Orthocell reported more than A$48 million in cash and no debt as at 31 March 2026.

Orthocell Ltd (ASX:OCC) shares advanced 4.17% to AUD 0.75 during the morning session on 3 July 2026 after the regenerative medicine company announced an expansion of its Asian commercial distribution network. The company appointed MediTime as the exclusive distributor of its nerve repair product Remplir in Thailand, providing a commercial pathway into an estimated US$84 million nerve repair market. While the stock remains down 39.52% over the past year, investors appeared to respond favourably to the latest step in Orthocell's broader commercialisation strategy across Asia.

Orthocell is an Australian regenerative medicine company focused on developing products designed to repair bone, tendon, nerve and soft tissue injuries. Its portfolio includes collagen-based medical devices and regenerative therapies used across dental, orthopaedic and nerve repair applications. The company continues to expand commercial access for its products in multiple international markets while progressing additional opportunities in the United States and Asia.

Thailand Appointment Expands Orthocell's Asian Commercial Network

Orthocell announced the appointment of MediTime as its exclusive in-country distributor for Remplir in Thailand, following regulatory approval from the Thai Food and Drug Administration during calendar year 2025 that allows commercial sales of the product in the country.

The agreement gives Orthocell an established commercial route into Thailand's peripheral nerve repair market, which the company estimates is valued at approximately US$84 million.

Thailand forms an important part of Orthocell's commercial strategy across Asia due to its developed healthcare system and established medical tourism industry. The company considers the country a key market for expanding the availability of advanced nerve repair solutions.

The latest appointment also strengthens Orthocell's growing distribution footprint across Asia, where Remplir is already being commercialised in Australia, Singapore and Hong Kong.

MediTime Brings Established Healthcare Market Access

Orthocell selected MediTime as its exclusive distribution partner because of the company's established position within Thailand's orthopaedic and sports medicine sector.

MediTime has developed relationships across leading hospitals, medical schools and regional healthcare centres throughout Thailand. Its commercial activities are concentrated in upper extremity orthopaedic surgery, providing Orthocell with direct access to surgeons involved in peripheral nerve repair procedures.

The distributor also operates a clinical education model supported by established relationships with key opinion leaders. According to Orthocell, this approach is expected to assist both the initial introduction of Remplir and broader market development over time.

In addition to surgeon education, MediTime offers a national logistics network and hospital access that may help facilitate product availability across Thailand's healthcare system.

Partnership Builds on Existing Regional Relationship

The appointment extends Orthocell's existing collaboration with Device Technologies Group, which currently distributes Remplir across Australia, New Zealand and Singapore.

MediTime operates with the support of Device Technologies Group's broader regional commercial infrastructure, allowing Orthocell to expand an established partnership rather than developing an entirely new distribution network.

The company noted that leveraging existing commercial relationships forms part of its broader strategy to grow international sales while efficiently entering additional markets.

By building upon partnerships already established within the region, Orthocell aims to expand commercial access for Remplir across Asia through specialist healthcare distributors with local market expertise.

Commercial Strategy Continues Across Non-U.S. Markets

Orthocell confirmed that it remains focused on executing a distributor-led commercial strategy across key international markets outside the United States.

Under this approach, specialist distribution partners are responsible for commercial activities within their respective territories, allowing the company to enter additional markets without committing significant incremental internal resources.

The Thailand appointment represents another step in implementing this strategy following earlier commercial launches in Australia, Singapore and Hong Kong.

The company indicated that its distributor-led model allows management to continue expanding internationally while maintaining a disciplined allocation of internal resources.

Internal Resources Remain Focused on the U.S. Opportunity

While international distributors continue supporting expansion across Asia and other non-U.S. markets, Orthocell stated that its internal commercial resources remain concentrated on the United States.

The company recently secured approvals that have expanded access for Remplir to approximately 336 hospitals across the United States, including 221 U.S. military medical centres.

Orthocell continues to pursue a company-led commercial strategy in the U.S. market while relying on distribution partners to support growth in other international regions.

This combination of direct commercial activities in the United States and distributor-led expansion elsewhere remains central to the company's broader commercialisation framework.

Financial Position Supports Ongoing Commercial Expansion

Orthocell also highlighted its financial position as it continues expanding internationally.

As at 31 March 2026, the company reported cash reserves exceeding A$48 million and stated that it remained debt free.

Management indicated that this financial position provides support for continued commercial expansion across existing and new markets while progressing broader growth initiatives.

The announcement did not include any changes to financial guidance or capital management plans, instead emphasising the company's existing balance sheet strength to support commercial execution.

Management Comments on the Thailand Expansion

Managing Director Paul Anderson described the appointment as an important milestone within Orthocell's Asian commercialisation strategy for Remplir.

Management noted that Thailand represents a developed healthcare market with demand for advanced nerve repair technologies and highlighted MediTime's established clinical relationships, education-focused approach and national distribution capabilities as key factors supporting the partnership.

The company also stated that the appointment further strengthens its ongoing relationship with Device Technologies Group as Orthocell continues expanding its distribution network throughout Asia.

About Orthocell

Orthocell develops regenerative medicine products designed to support tissue repair and reconstruction across orthopaedic, dental and nerve repair applications.

Its portfolio includes Striate+, a collagen membrane used in guided bone regeneration procedures that has received regulatory clearance across multiple international markets, including the United States, Australia, Europe, Canada, Brazil, Singapore, New Zealand and the United Kingdom.

Remplir, the company's peripheral nerve repair product, has received approvals in Australia, New Zealand, Singapore, Thailand, Hong Kong, Canada and the United States. Orthocell has also appointed specialist distributors across the U.S. market and has already recorded initial sales following regulatory clearance.

The company's broader product portfolio also includes SmrtGraft for tendon repair, together with regenerative cell therapies targeting tendon and cartilage repair.

What Could Investors Watch Next?

Following the latest announcement, investors are likely to monitor the commercial rollout of Remplir in Thailand through MediTime and the progress of product adoption within the country's healthcare system.

Market participants may also watch further expansion of Orthocell's distributor network across additional international markets, alongside developments in the company's U.S. commercial strategy, where access has recently expanded to approximately 336 hospitals, including 221 U.S. military medical centres.

The company's execution of its distributor-led strategy across Asia and its continued deployment of available cash resources may also remain areas of investor focus.